FIGURE 5.

a) A comparison of long-term patient survival between the treatment groups. L-CsA: liposomal cyclosporine; SOC: standard of care. As of September 2017, 45% of patients (five out of 11) randomised to the inhaled L-CsA arm were alive, while 0% of patients (none out of 10) randomised to the SOC-alone arm were alive (p=0.03). Median patient survival was 4.1 years for L-CsA compared with 2.9 years for SOC-alone. b) A comparison of long-term graft survival between the treatment groups. As of September 2017, 45% of patients (five out of 11) randomised to the L-CsA arm were alive and free of re-transplantation (one re-transplantation occurred) compared with 0% of patients (none out of 10) randomised to the SOC-alone arm (three re-transplantations occurred) (p=0.01). Median graft survival was 4.1 years for L-CsA compared with 2.7 years for SOC-alone.